Journal article
First 20 years with recombinant FVIIa (NovoSeven).
- Abstract:
-
This review describes the background for the development of recombinant FVIIa (rFVIIa; NovoSeven) for use in haemophilic patients with inhibitors. The first proof of principle for using pharmacological doses of FVIIa as a haemostatic agent was obtained by producing small amounts of pure plasma-derived FVIIa, which showed encouraging effect in two patients with haemophilia A and inhibitors. To make pure FVIIa available for use in a larger number of patients, rFVIIa was produced that was approv...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Haemophilia : the official journal of the World Federation of Hemophilia
- Volume:
- 17
- Issue:
- 1
- Pages:
- e172-e182
- Publication date:
- 2011-01-01
- DOI:
- EISSN:
-
1365-2516
- ISSN:
-
1351-8216
- Source identifiers:
-
219796
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:219796
- UUID:
-
uuid:afe16ef3-c776-4350-8d58-6d4f986dd23a
- Local pid:
- pubs:219796
- Deposit date:
- 2014-11-08
Terms of use
- Copyright date:
- 2011
If you are the owner of this record, you can report an update to it here: Report update to this record